Many patients benefit from combining metformin with SGLT2 inhibitors or GLP1 receptor agonists for added cardiovascular and renal protection
We incorporated our genetic findings into broader models that combine demographic, clinical and genetic features to predict efficacy and side effects, and demonstrated the ability of this model to stratify patients by weight loss in a held out electronic health record (EHR) dataset
C., Kumar, A., Placone, J
Factors That Influence PT-141 Dosage and Response Hormonal Balance Hormones such as testosterone and estrogen directly influence sexual response
Weight Loss Coverage Has Flatlined and Some Employers Are Cutting It Employer coverage of GLP-1s for weight loss sat at 36% in both 2025 and 2026 , after climbing from 26% in 2023
This aspect is essential for projects requiring extended observation periods or those focused on the effects of sustained peptide administration